Grail Inc. Shares Reach $151.48 Record High Following Regulatory News

Grail Inc. (GRAL) reached an all-time high of $151.48, completing a rally where the stock price climbed 144.1% over the past year. The surge follows positive regulatory developments for the company’s Galleri multi-cancer early detection test. The stock’s rapid ascent has prompted a wide divergence in analyst sentiment regarding its valuation.

As of the close on October 9, 2026, Grail shares settled at $140.58, marking a 6.0% increase from the previous session's close of $132.61. This performance reflects investor optimism regarding the company's efforts to secure broader clinical adoption for its liquid biopsy technology.

Analyst Sentiment and Price Targets

Wall Street firms are divided on the company’s current market position, as price targets lag behind the stock's record highs. Recent adjustments include:

• Canaccord Genuity: Maintains a Buy rating and raised its price target to $150 from $80, citing a favorable FDA advisory committee vote on the Galleri test.
• Mizuho: Maintains a Neutral rating while increasing its price target to $100 from $65.
• RBC Capital: Initiated coverage with a Sector Perform rating and an $84 price target.

Canaccord Genuity expressed confidence in the company’s regulatory trajectory, but other analysts signaled caution. RBC Capital’s initiation highlighted concerns regarding the long-term path for insurance reimbursement and the speed of market adoption for cancer screening tools in clinical settings.

Regulatory and Market Context

The positive FDA advisory committee feedback served as a primary catalyst for the recent volatility and price appreciation. The Galleri test is designed to detect multiple types of cancer through a single blood draw, a technology that differs from traditional screening methods like colonoscopies or mammograms.

For the company, the core challenge is the transition from clinical validation to commercial scale. The wide gap between the current market price and the more conservative analyst targets underscores the uncertainty surrounding how quickly healthcare systems will integrate such tests into standard care and how the associated reimbursement models will function once fully implemented.